It’s now almost nine years since the first CAR-T therapies, Kymriah and Yescarta, were approved by the FDA. These therapies and others have revolutionised the treatment of certain hard-to-treat blood cancers, such as ALL and some B-cell lymphomas. There was rightly huge elation at the time. CAR-Ts were a real breakthrough, offering a lifeline – […]
Despite the short Bank Holiday week, it’s as busy as ever. Collaborative expansion is in full swing as Bonito Biosciences and DaltonTx join forces, and ViCentra triples Kaleido consumables production capacity through Phillips Medisize partnership. Hansa Biopharma, Poolbeg Pharma and Synklino have been enjoying progress this week, as Hansa reports positive efficacy and safety results […]
ARE vaccines coming in from the cold? That’s the question this week after Eli Lilly splashed out almost $4 billion on three vaccine biotechs, two of which are in the early stage of clinical development. All are developing jabs for or related to infectious diseases. Why’s this a big deal? Because everyone knows that […]
Follows successful completion of pre-clinical activities by Alchemab as part of earlier licensing deal with Eli Lilly and Company for ATLX-1282 Financing included participation from Eli Lilly and Company and Ono Venture Investment alongside significant support from world-class existing investors Cambridge, UK, 9 September 2025 – Alchemab Therapeutics (Alchemab), a biopharmaceutical company which identifies and develops […]
